SCHEMBL30965348

SCHEMBL30965348

Cc1ccc(C2C(=O)Nc3ccc(Cl)cc32)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.41
BRD4 O60885 2/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 3/20 0.38
TP53 P04637 2/20 0.38
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
SLC8B1 Q6J4K2 1/20 0.38
CDYL2 Q8N8U2 1/20 0.37
CDYL Q9Y232 1/20 0.37
ATM Q13315 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29242310 1.00 PGR (0.41) PGRBRD4POLBMAPTTP53
SCHEMBL30965339 0.89 PGR (0.38) PGRPOLBMAPTTP53PDE4A
SCHEMBL3966480 0.89 PGR (0.38) PGRPOLBMAPTTP53PDE4A
SCHEMBL30965341 0.85 BRD4 (0.43) PGRBRD4POLBMAPTTP53
SCHEMBL29242301 0.85 BRD4 (0.43) PGRBRD4POLBMAPTTP53
SCHEMBL29242355 0.85 BRD4 (0.41) BRD4POLBMAPTTP53CYP1A2
SCHEMBL30965343 0.85 BRD4 (0.41) BRD4POLBMAPTTP53CYP1A2
SCHEMBL29242350 0.80 PGR (0.41) PGRPOLBMAPTTP53TSHR
SCHEMBL30965344 0.80 PGR (0.41) PGRPOLBMAPTTP53TSHR
SCHEMBL7463659 0.79 BRD4 (0.51) PGRBRD4MAPTTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221565-A 3-Aryl indol-2-one compound with anticancer activity and application thereof in preparation of medicines for treating cancers 常州大学 2024-06-21 CN disclosed